Biotechnology company, Allievex Corporation, enters licensing agreement with BioMarin.

25 Oct 2019

BioMarin has licenced its enzyme replacement therapy that is in clinical trial for Sanfilippo type B to a company called Allievex. BioMarin has assured us that all clinical trial activity will continue under the new company.

 

Click here to read the full article

If you have any questions or concerns, you can contact BioMarin’s Medical Information Services below:

Email: medinfoasia@bmrn.com

Phone: 1800 387 876 or (02) 85203255